Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
HCC70 | Cediranib | VEGFR/cKIT | RTK | 4.5386 | -0.3262 | 0.0890 | 0.0440 | 2.2440 | 7.4053 | 0.99062 |
MDA-MB-231 | Alpelisib | PI3Ka | PI3K/mTOR | 48.2918 | 0.6904 | 0.0895 | 0.0045 | 0.4504 | 553.5356 | 0.61498 |
HME1 | ABT-737 | Bcl2/XL | Misc | Inf | 0.4949 | 0.0896 | 0.0303 | 5.0000 | 1.1036 | 0.96879 |
Hs 578T | Alpelisib | PI3Ka | PI3K/mTOR | 11.8954 | 0.5308 | 0.0905 | 0.0063 | 0.7199 | 54.7171 | 0.9693 |
CAL-51 | Neratinib | EGFR/HER2 | RTK | 2.2484 | 0.2802 | 0.0910 | 0.0109 | 1.5163 | 4.6402 | 0.98601 |
MDA-MB-436 | PF-4708671 | p70S6K | PI3K/mTOR | 4.7528 | 0.1938 | 0.0918 | 0.0048 | 1.3212 | 6.5976 | 0.98815 |
CAL-120 | Alpelisib | PI3Ka | PI3K/mTOR | 21.5328 | 0.6075 | 0.0922 | -0.0015 | 0.5034 | 190.956 | 0.93579 |
HCC1143 | Olaparib | PARP | Misc | 8.8262 | 0.4562 | 0.0925 | 0.0158 | 0.7545 | 37.8573 | 0.98047 |
MDA-MB-453 | Cisplatin | Chemo | Chemotherapy | 3.4106 | 0.1328 | 0.0938 | -0.0013 | 3.0256 | 3.151 | 0.9887 |
HCC1395 | TGX221 | PI3Kb | PI3K/mTOR | 8.4625 | 0.4581 | 0.0950 | 0.0125 | 0.6815 | 16.0341 | 0.94431 |
MCF 10A | Cisplatin | Chemo | Chemotherapy | 4.2937 | 0.3794 | 0.0952 | 0.0149 | 2.1287 | 2.4561 | 0.99519 |
HCC1806 | Olaparib | PARP | Misc | 10.3367 | 0.4886 | 0.0953 | 0.0224 | 0.7744 | 42.7088 | 0.92848 |
SUM1315MO2 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 0.5951 | 0.0977 | 0.0059 | 0.9518 | 1.3643 | 0.93531 |
MDA-MB-134-VI | Cediranib | VEGFR/cKIT | RTK | 4.2103 | -0.9999 | 0.0977 | 0.0979 | 5.0000 | 5.2449 | 0.99321 |
SK-BR-3 | Cisplatin | Chemo | Chemotherapy | 5.1075 | 0.2490 | 0.0978 | 0.0114 | 1.4151 | 5.7965 | 0.99044 |
HCC1500 | Olaparib | PARP | Misc | 6.3506 | 0.2744 | 0.0985 | 0.0084 | 1.0887 | 17.4212 | 0.94589 |
SUM1315MO2 | ABT-737 | Bcl2/XL | Misc | 5.9406 | 0.3056 | 0.0987 | 0.0360 | 0.8016 | 23.3924 | 0.93756 |
Hs 578T | Olaparib | PARP | Misc | 8.9082 | 0.4435 | 0.0997 | 0.0101 | 1.0369 | 25.6993 | 0.93656 |
HCC38 | Saracatinib | SRC | MAPK/nRTK | 29.3313 | 0.6139 | 0.1013 | 0.0162 | 0.4862 | 24.1837 | 0.94737 |
HCC38 | Neratinib | EGFR/HER2 | RTK | 3.1556 | 0.4571 | 0.1019 | 0.0168 | 0.7043 | 15.0154 | 0.87632 |
HME1 | Cabozantinib | VEGFR2/MET | RTK | 3.2402 | -0.1052 | 0.1020 | 0.0260 | 2.6885 | 3.6278 | 0.98973 |
MDA-MB-436 | Dasatinib | BCR/ABL | MAPK/nRTK | Inf | 0.6528 | 0.1022 | 0.0098 | 0.0000 | Inf | 0.40773 |
HCC1143 | Cabozantinib | VEGFR2/MET | RTK | 10.6105 | 0.5122 | 0.1025 | 0.0156 | 0.9383 | 34.2157 | 0.84631 |
HCC1143 | ABT-737 | Bcl2/XL | Misc | 6.1992 | 0.3758 | 0.1027 | 0.0110 | 0.8672 | 8.5825 | 0.98522 |
MDA-MB-468 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.7230 | 0.1032 | 0.0343 | 0.5264 | 0.7426 | 0.94963 |